Expression of p-mTOR and p70s6k in non-small-cell lung cancer and its clinical significance
XU Haoran
LYU Yanchao
HAN Shuangshuang
WANG Lihong
YUE Hongjuan
WANG Jia
Abstract：Objective To observe the expression changes of phosphorylated mammalian target of rapamycin (p-mTOR) and p70s6k protein in non-small-cell lung cancer (NSCLC) tissues and to discuss its clinical significance .Meth-ods Eighty-two cases of patients with NSCLC were selected .The tumor tissues obtained from surgery (lung cancer group) , 46 cases of tissue samples from alveolus healthy tissues (control group 1) , and 50 cases of tissue samples from bronchus mucosal tissues (control group 2) were collected.The expression of p-mTOR and p70s6k protein in the three groups was measured by immunohistochemistry and we analyzed the relationships with the clinical and pathological data . Results The positive expression rates of p-mTOR protein in the lung cancer group , control group 1 and control group 2 were 68.29%, 17.39% and 32.0%, respectively.The positive expression rates of p70s6k protein in the lung cancer group, control group 1 and control group 2 were 85.37%, 21.74%and 32.00%, respectively.Significant difference was found between the lung cancer group and the control group 1, control group 2 (all P＜0.01).The expression of p-mTOR protein in poorly differentiated cancer tissues was significantly higher than that of medium and high differentiation cancer tis -sues (P＜0.01).In the NSCLC tissues, the p-mTOR and p70s6k expression was positively correlated (r=0.210, P=0.0032).Conclusion p-mTOR and p70s6k protein is highly expressed in NSCLC tissues , which may be used as the early-warning index in the early diagnosis or as a new target for anti-cancer drug.
Keywords：lung neoplasmsnon-small-cell lung cancerphosphorylated mammalian target of rapamycinp70s6k
Publication Date：2016-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 11-13 )